Novel drugs for Renal cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 17, Issue 10, 2008, Pages 1501-1516

  Vakkalanka, Bhanu K ^a   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Axitinib; Bevacizumab; Ceditanib; Everolimus; Mammalian target of rapamycin kinase; Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapy; Temsirolimus; Tyrosine kinase inhibitors; VEGF; Volociximab

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CANCER VACCINE; CEDIRANIB; CYTOTOXIC AGENT; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEMCITABINE; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VOLOCIXIMAB;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASCITES; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FISTULA; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPONATREMIA; IC 50; INFECTION; INTESTINE PERFORATION; JAUNDICE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; LIMB PAIN; LOW DRUG DOSE; LUNG EMBOLISM; MACULOPAPULAR RASH; MANIC DEPRESSIVE PSYCHOSIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; NOSE SEPTUM PERFORATION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PNEUMONIA; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR BLEEDING; TUMOR NECROSIS; TUMOR PERFORATION; VENOUS THROMBOEMBOLISM; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; KIDNEY NEOPLASMS; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; SIROLIMUS; SULFONAMIDES;

EID: 52949089716     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.10.1501     Document Type: Review

References (88)

1. International Agency for Research on Cancer
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66
4. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11(1):37-42
5. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004
6. Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22(3):200-9
7. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275(33):25733-41
8. Igarashi H, Esumi M, Ishida H, et al. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002;95(1):47-53
9. Sulzbacher I, Birner P, Traxler M, et al. Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 2003;120(1):107-12.
10. Scanga SE, Ruel L, Binari RC, et al. The conserved PI3'K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila. Oncogene 2000;19(35):3971-7
11. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008;14(5):1286-90
12. Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006;5(4):279-80
13. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fl uoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46(7):1116-9
14. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced enal cell carcinoma. Clin Cancer Res 2007;13(5):1367-73
15. Rini BI. Sunitinib. Expert Opin Pharmacother 2007;8(14):2359-69
16. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23(5):1028-43
17. Chouhan JD, Zamarripa DE, Lai PH, et al. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. J Oncol Pharm Pract 2007;13(1):5-15
18. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
19. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005;11(16):5827-32
20. Ikezoe T, Yang Y, Nishioka C, et al. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006;97(9):45-951
21. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91(10):4070-6
22. Patyna S, Laird AD, Mendel DB, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006; 5 (7): 1774-82
23. Anonymous. Sutent-package insert, Pfizer; 2006
24. Anonymous. Pfizer product information label; 2007
25. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17(3):353-8
26. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
27. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105(3):986-93
28. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
29. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
30. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
31. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). ASCO annual meeting proceedings [abstrart 5024]. J Clin Oncol 2008; 26 (Suppl)
32. Murphy DA, Makonnen S, Lassoued W, et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006;169(5):1875-85
33. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
34. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
35. Wilhelm SM, Christopher C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
36. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11(15):5472-80
37. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855-61
38. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16(10):1688-94
39. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13(6):1801-9
40. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12
41. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (18S Suppl): 5025
42. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
43. Bukowski R, Cella D, Gondek K, et al. Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;30(3):220-7
44. Amato RJ, Harris P, Dalton M, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). 2007 ASCO Annual Meeting Proceedings Part I. J Clini Oncol 2007;25(18S Suppl):5026
45. Rini BI, Hutson TE, Elson P, et al. A prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract 346]. 2008 ASCO Genitourinary Cancers Symposium
46. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
47. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975-84
48. Dutcher JP, Wilding G, Hudes GR, et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone [abstract 5127]. J Clin Oncol 2008;26(Suppl)
49. Axitinib (AG-013736) as second line therapy for metastatic renal cell cancer: AXIS trial, clinical protocol A4061032, Pfizer
50. Wedge SR, Kendrew J, Laurent F, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400
51. Fiedler W, Mesters R, Heuser M, et al. An open phase I study of cediranib (Recentin, AZD2171) in patients with acute myeloid leukemia (AML) [poster 895]. Am Soc Hematol 2007
52. Sridhar SS, MacKenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium [abstract 5047]. J Clin Oncol 2008;26(Suppl)
53. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21
54. Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors [abstract 3012]. J Clin Oncol 2005;23:195s
55. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5031
56. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2(4):296-313
57. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001;98(18):10314-9
58. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22(12):2336-47
59. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18
60. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96
61. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22)-1271-81
62. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12(17):5165-73
63. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588-95
64. Amato RJ, Misellati A, Khan M, et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S Suppl):4530
65. Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VFGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study [abstr LBA5026]. J Clin Oncol 2008;26(Suppl)
66. Melnyk O, Zimmerman M, Kim KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and merastases in a pre-clinical model. J Urol 1999;161(3):960-3
67. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843-50
68. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
69. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib, combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41
70. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
71. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19(8):1470-6
72. Rini BL, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract 350]. 2008 ASCO Genitourinary Cancers Symposium
73. Ricart A, Liu G, Tolcher A, et al. A phase I dose-escalation study of anti-α5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors [abstract 166]. Eur J Cancer 2004;2(Suppl):52
74. Figlin RA, Kondagunta GV, Yazji S, et al. Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic dear cell renal cell cancer (RCC) 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2006;24(18S Suppl):535
75. Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol 2006;33(5):534-43
76. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127-31
77. Golshayan AR, George S, Heng DY, et al. Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy [abstract 5102]. J Clin Oncol 2008:26(20 Suppl)
78. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101(7):1545-51
79. Dutcher JP, De Souza P, Figlin R, et al. Effect of temsirolimus versus interferon-α on survival of patients with advanced renal cell carcinoma of different tumor histologies [abstract 384). 2008 ASCO Genitourinary Cancers Symposium
80. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22(1):42-60
81. Slovin SF, Motzer RJ, Jefferson M, et al. Phase I trial of a PSMA DNA vaccine for patients (pts) with good risk renal cell carcinoma (RCC) [abstract 16073]. J Clin Oncol 2008;26(20 Suppl)
82. Johannsen M, Roemer A, Spitaleri G, et al. Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma [abstract 16032]. J Clin Oncol 1008;26(Suppl)
83. Dupont J, Schwartz L, Koutcher J, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol22(14S Suppl):3009
84. Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGT Trap in a phase I clinical trial of patients with advanced solid tumors. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol23(16S Suppl) (Pt I of II):3029
85. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25(22):3288-95
86. Wood L, Bukowski RM, Dreicer R, et al. Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy [abstract 3531. 2008 ASCO Genitourinary Cancers Symposium
87. Radimell K, Amin C, Wallen E, et al. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC) [abstract 370]. 2008 ASCO Genitourinary Cancers Symposium
88. Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [abstract 5008]. J Clin Oncol 2008;26(Suppl)